Disposal of own shares

Brussels (Belgium), 2 June 2022 – 20:00 (CEST) – Regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following an exercise of stock options by a member of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant member of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

This press release is available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations

Antje Witte 

T +32 2 559 94 14

antje.witte@ucb.com

Corporate Communications

Laurent Schots 

T+32 2 559 92 64

laurent.schots@ucb.com     

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news